In announcing the award, the judges declared that “in comparison to existing medications, FORTIBONE® has a signalling effect on osteoblasts to counterbalance the collagen degradation in the extracellular bone matrix, which is the essential framework for bone mineralization”. With its special mode of action it is thus said to be a good addition to existing treatment options for osteoporosis, as most existing medications have an anticatabolic effect and can cause side-effects. The award win was aided by a high quality scientific study showing significant increase in bone mineral density of 5–7 % in the spine and the femoral neck after FORTIBONE® supplementation, and a clear anabolic effect, which was determined by biomarker concentrations.
Osteoporosis has serious health implications, not just for the wellbeing of individuals, but also the population as a whole. It is estimated that, globally, one in three women and one in five men over the age of 50 will sustain an osteoporotic-induced bone fracture during their lifetime. In the EU alone, the number of these incidences is predicted to grow by 28 per cent from 2010 to 2025, resulting in economic costs of more than EUR 45 billion.
“We’re very proud to have received this award because it underlines the innovative power of our company, and honours our efforts to prove the efficacy of all products with high quality scientific studies,” stated Michael Teppner, Global VP Marketing and Communication at GELITA. “I like to think of FORTIBONE® as the missing piece of the jigsaw when it comes to bone health management. And the best part besides its efficacy is that – as with all GELITA collagen peptides – FORTIBONE® is made exclusively from natural proteins, so it doesn’t have an E-number and delivers truly natural functionality.“